上海锦斯生物技术

Jinsi Biotech is a clinical-stage biotechnology company headquartered in Shanghai, China, dedicated to the advancement of AAV-based gene therapies. The company leverages its proprietary Jinsi-AAV platform to design and manufacture high-titer, high-purity viral vectors for treating rare genetic diseases. Their internal pipeline includes candidates for Leber's Hereditary Optic Neuropathy (LHON), Spinal Muscular Atrophy (SMA), and Duchenne Muscular Dystrophy (DMD). In addition to its R&D efforts, Jinsi Biotech provides CDMO services to the global biopharmaceutical industry, supported by its state-of-the-art GMP manufacturing facilities. The company is backed by prominent investors such as HighLight Capital and Qiming Venture Partners. Jinsi Biotech aims to provide affordable and effective gene therapy solutions for patients with unmet medical needs worldwide.